[Diabetic arteriopathy. Microcirculation, an inevitable therapeutic objective]

Area of Science:

• Vascular Biology and Medicine
• Diabetic Complications
• Microcirculation Research

Context:

• Severe arteriopathy presents with multifocal macrovascular lesions, impairing tissue perfusion and leading to microcirculatory dysfunction.
• Diabetic autonomous neuropathy exacerbates endothelial dysfunction, contributing to capillary obstruction and irreversible tissue damage.
• Current treatment goals focus on delaying microcirculatory destruction, especially after macrovascular interventions like angioplasty or surgery.

Purpose:

• To explore the potential therapeutic roles of endothelial-derived relaxing factor (EDRF, or nitric oxide) and prostacyclin in managing severe arteriopathy.
• To highlight the synergistic inhibitory effects of NO and prostacyclin on platelet and leukocyte activation.
• To emphasize the need for earlier and more precise detection of microcirculatory alterations for optimal patient management.

Summary:

• In advanced arteriopathy, endothelial dysfunction, aggravated by diabetic neuropathy, leads to capillary obstruction and irreversible tissue compromise.
• Nitric oxide (NO) and prostacyclin show theoretical potential in inactivating activated cells and restoring flow due to their vasodilatory and anti-aggregatory properties.
• Therapeutic drug trials have shown limited success, underscoring the importance of timely intervention before severe microcirculatory damage.

Impact:

• Advances in early microcirculation detection can significantly improve the management of lower limb arteriopathy through timely angioplasty or surgery.
• Understanding the roles of NO and prostacyclin may lead to novel therapeutic strategies for severe ischemic conditions.
• This research underscores the critical window for intervention in preventing irreversible tissue damage in arteriopathy patients.